Login
Companies $EYPT
$0.29 -$0.02 (5.95%) After hours
EyePoint, Inc. logo

EyePoint, Inc.

eyepoint.bio

What Do They Do?

Develops sustained-delivery drug treatments for patients with serious retinal diseases, including wet age-related macular degeneration and diabetic macular edema.

How Do They Make Money?

Pharmaceutical partners pay upfront license fees and milestone payments when specified goals are met; EyePoint also receives royalties when partners sell licensed products. It earns product revenue through commercial supply agreements.

revenue
SegmentShareRevenue
Product sales, net
5.1%
FY2022: 96%
License and Collaboration Agreement
Licensed

53%
FY2022: 0.9%
Royalty Income
Licensed

42%
FY2022: 2.8%

Who Are Their Customers?

Pharmaceutical partners license rights to develop and commercialize products; EyePoint also supplies products to partners under commercial supply agreements, including ANI for U.S. sales.

Do Revenues Turn Into Profits?

No. It lost $232M in FY2025.

Operating income, FY2025
−776% of revenue
▼ −67% (Loss) vs FY2024 (−$145.9M, −337%)
Net income, FY2025
−739% of revenue
▼ −77% (Loss) vs FY2024 (−$130.9M, −302%)
Free cash flow, FY2025
−776% of revenue
▼ −87% (Loss) vs FY2024 (−$130.3M, −301%)

How Are They Changing?

Since the FY2025 annual report
  • Nov 12, 2026 Both pivotal wet AMD trials missed their primary endpoints EyePoint said it would end both trials early while assessing further analyses.
  • Oct 17, 2026 Redirects resources to DME and plans a workforce reduction The plan includes ending the wet AMD trials early and reducing the workforce.

Shrinking. Revenue fell 15% in 4 years, from $36.9M in FY2021 to $31.4M in FY2025, about 4% a year.

Partner-led product commercialization The older report described YUTIQ as a product EyePoint marketed; the latest report describes a license to ANI for development and commercialization, with EyePoint earning license revenue.

Lead candidate advances The lead candidate moved from earlier studies for wet AMD and non-proliferative diabetic retinopathy, with DME development planned, to pivotal trials for wet AMD and diabetic macular edema.

Revenue over time
Product sales, net License and Collaboration Agreement Royalty Income Collaborative Research and Development
$50M$25M$0

Who Do They Compete With?

Competes with REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, Merck, Ollin Biosciences, Ocular Therapeutix, Kodiak Sciences, and Oculis Holding

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support